Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure

NCT02678312 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

393

Enrollment

INDUSTRY

Sponsor class

Conditions

Pediatric Heart Failure

Interventions

DRUG: LCZ696
DRUG: Enalapril
DRUG: Placebo of LCZ696
DRUG: Placebo of Enalapril
DRUG: LCZ696

Sponsor

Novartis Pharmaceuticals